Study of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute Enrols First Patient
Kazia Therapeutics Limited (NASDAQ: KZIA
Study of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute Enrols First Patient
Kazia Therapeutics Limited (NASDAQ: KZIA